tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ross Osborn, 171 are a BUY (92.43%), 14 are a HOLD (7.57%).
Analyst Ross Osborn, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 36.16% that have a potential upside of 54.02% achieved within 199 days.
Ross Osborn’s has documented 360 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on PRE, Prenetics Global Ltd at 10-Nov-2025.
Analyst best performing recommendations are on NPCE (NEUROPACE).
The best stock recommendation documented was for NPCE (NEUROPACE) at 5/14/2025. The price target of $17 was fulfilled within 1 day with a profit of $1.4 (8.97%) receiving and performance score of 89.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell Since 14-Apr-2026
$1.5
$-0.15 (-9.09%)
$1
4 months 1 days ago
(11-May-2026)
5/8 (62.5%)
$0.14 (10.29%)
25
Hold Since 16-May-2022
$2
$0.35 (21.21%)
$1.5
10 months 1 days ago
(11-Nov-2025)
13/14 (92.86%)
$0.14 (7.53%)
98
Buy Since 18-Feb-2025
$2
$0.35 (21.21%)
$1.8
10 months 2 days ago
(10-Nov-2025)
3/3 (100%)
$0.24 (13.64%)
150
Buy Since 10-Jun-2020
$3
$1.35 (81.82%)
$3
10 months 28 days ago
(15-Oct-2025)
5/12 (41.67%)
$1.26 (72.41%)
160
Buy Since 03-Jun-2024
$3
$1.35 (81.82%)
1 years 4 months 3 days ago
(09-May-2025)
1/2 (50%)
$1.88 (167.86%)
40
What Year was the first public recommendation made by Ross Osborn?
